<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1998">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135156</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00011578</org_study_id>
    <secondary_id>1R03HL158728-01</secondary_id>
    <nct_id>NCT05135156</nct_id>
  </id_info>
  <brief_title>Lung Transplant READY Pilot Study</brief_title>
  <official_title>Lung Transplant Resources for Education and Decision-making for Your Cystic Fibrosis (READY): A Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF).&#xD;
      More than half of people with CF who die without a lung transplant were never referred for&#xD;
      consideration. Patient preference not to undergo lung transplant may account for 25-40% of&#xD;
      decisions to defer referral. Increasing awareness of lung transplant among people with CF,&#xD;
      and promoting understanding of the risks and benefits of transplant, can potentially reduce&#xD;
      the number of people with CF who die without a lung transplant.&#xD;
&#xD;
      The CF Foundation (CFF) lung transplant referral guidelines were developed to optimize the&#xD;
      timing of referral for lung transplant. These guidelines recommend annual conversations with&#xD;
      CF patients once their forced expiratory volume in one second (FEV1) is &lt;50% predicted.&#xD;
      Considering lung transplant as a treatment option ahead of when it is medically needed will&#xD;
      allow more time to learn about lung transplant and address any barriers to lung transplant&#xD;
      that may exist.&#xD;
&#xD;
      Investigators are interested in understanding how people with CF use lung transplant&#xD;
      educational resources and how one prepares for having discussions and/or making decisions&#xD;
      about lung transplant as a treatment option for advanced CF. The purpose of this study is to&#xD;
      test whether a research website improves patient preparedness for discussions about lung&#xD;
      transplant.&#xD;
&#xD;
      Study involvement will span 4 weeks and study procedures will involve the following:&#xD;
&#xD;
        -  Three Zoom interview sessions (30-60 minutes each)&#xD;
&#xD;
        -  Survey assessments&#xD;
&#xD;
        -  Access to a research website that contains educational resources about lung transplant&#xD;
           (goal of 4 hours of use over the 4 week study period)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In&#xD;
      the United States, more CF patients with forced expiratory volume in 1 second (FEV1) less&#xD;
      than 30% of predicted die each year than undergo lung transplant. More than half of people&#xD;
      with CF who die without lung transplant were never referred for consideration, with patients&#xD;
      of lower socioeconomic status disproportionately impacted by limited access to lung&#xD;
      transplant. Patient preference not to undergo lung transplant may account for 25-40% of&#xD;
      decisions to defer referral. The CF Foundation established lung transplant referral&#xD;
      guidelines that recommend individuals with CF have annual conversations about lung transplant&#xD;
      with their CF doctor once their FEV1 is less than 50% of predicted. Considering lung&#xD;
      transplant as a treatment option ahead of when it is medically needed will allow more time to&#xD;
      learn about lung transplant and address any barriers to lung transplant that may exist. By&#xD;
      introducing an educational resource that can increase awareness of lung transplant among&#xD;
      patients, and promote understanding of the risks and benefits of lung transplant,&#xD;
      investigators aim to empower people with CF to take part in shared decision-making with their&#xD;
      CF providers which could reduce the number of people with CF who die without lung transplant.&#xD;
&#xD;
      Based on prior research, investigators have developed a novel lung transplant decision&#xD;
      support tool that addresses patient-identified knowledge gaps and provides personalized&#xD;
      educational content to help people with CF prepare for lung transplant discussions and&#xD;
      decisions. The decision support tool couples real-life CF patient experiences of lung&#xD;
      transplant in the form of personal narratives with up-to-date, CF-specific, and&#xD;
      guideline-based medical information about lung transplant.&#xD;
&#xD;
      The overall research objectives for this pilot study are to test the efficacy of the decision&#xD;
      support tool to improve patient preparedness for shared decision making about lung transplant&#xD;
      and knowledge about lung transplant, and to evaluate the impact on mental health outcomes&#xD;
      (depression and anxiety). The new website will be compared against an attention control&#xD;
      website (UNOS.org) to better understand how people with CF use and rank different educational&#xD;
      resources' utility. The central hypothesis is that use of the new decision support tool that&#xD;
      incorporates disease severity data (FEV1 % predicted, supplemental oxygen use, exacerbations)&#xD;
      to identify relevant personal narratives and guideline-based educational content will&#xD;
      increase a patient's preparedness to engage in discussions about lung transplant beyond the&#xD;
      standard information presented on UNOS.org.&#xD;
&#xD;
      The pilot study will be a randomized controlled trial. Participants will be randomized 1:1 to&#xD;
      one of two educational resources, described above, stratified by FEV1 category (FEV1 30-50%&#xD;
      or FEV1 &lt;30% of predicted). Baseline surveys will evaluate knowledge about lung transplant, a&#xD;
      Likert scale rating of preparedness for lung transplant discussions, decisional conflict&#xD;
      about lung transplant, and mental health. Baseline interviews will address perspectives on&#xD;
      lung transplant as a treatment option for CF and the role of newer CF therapies in the&#xD;
      decision making process about lung transplant. For two weeks, participants will have access&#xD;
      to one of two educational resources via a login to a secure research website. At 2 weeks,&#xD;
      there will be a study visit that includes repeated surveys from baseline and the Preparedness&#xD;
      for Shared Decision Making (PrepDM) Scale, along with a second brief interview. After the&#xD;
      2-week study visit, participants will have access to both educational resources via&#xD;
      individual login to the secure research website. At 4 weeks, there will be a study visit to&#xD;
      repeat the surveys and interview. Throughout the 4 weeks, web analytics will be captured at&#xD;
      the individual level to determine usage patterns for both educational resources.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of participants completing 2-week study visit</measure>
    <time_frame>Measured at 2-week study visit</time_frame>
    <description>The co-primary endpoint is feasibility, which will be defined as successful if 90% of enrolled participants complete the 2-week study visit (regardless of study arm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preparedness for Shared Decision Making (PrepDM) Scale</measure>
    <time_frame>Measured at 2-week study visit</time_frame>
    <description>The co-primary endpoint is an intention-to-treat assessment of the difference in mean Preparedness for Shared Decision Making (PrepDM) Scale in the intervention versus control arms of the study at the 2-week study visit. Scores range on a scale from 0 to 100 with higher scores indicating a higher perceived level of preparation for decision making.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey)</measure>
    <time_frame>Measured at 2-week study visit</time_frame>
    <description>Difference in mean confidence-weighted true false (CTF) knowledge score will be measured in the intervention versus control arms of the study. CTF scoring adds points for certainty in correct responses and deducts points for certainty in incorrect responses. Participants receive +2 points when &quot;sure&quot; about a correct response, +1 if unsure about a correct response, -1 if unsure about an incorrect response and -2 if sure about an incorrect response. For a 14-item knowledge test, the maximum score is +28 and the minimum score is -28, with higher scores indicating more knowledge about lung transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decisional Conflict Scale</measure>
    <time_frame>Baseline to 2-week study visit</time_frame>
    <description>Decisional Conflict Scale change will be measured from the baseline study visit to the 2-week study visit. The intention-to-treat analysis will compare mean change in the Decisional Conflict Scale between the intervention and control arms of the study. Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likert-scale rating of preparedness to discuss lung transplant (0-4)</measure>
    <time_frame>Measured at 2-week study visit</time_frame>
    <description>Likert rating of preparedness will be measured at the 2-week study visit (0=Don't know, 1= Not at all prepared, 2 = A little prepared, 3 = Moderately prepared, 4 = Very prepared). The intention-to-treat analysis will compare mean Likert-scale rating between the intervention and control arms of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Measured at 2-week study visit</time_frame>
    <description>PHQ-9 is a scale that measures symptoms of depression in the prior 2 weeks on a 0-27 scale, with higher scores indicating worsening depression and a score of 10 or higher consistent with a diagnosis of depression. Investigators will assess the difference in mean PHQ-9 score in the intervention versus control arms of the study at the 2-week study visit. Investigators will also determine the proportion with new PHQ-9 score greater than or equal to 10 in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generalized Anxiety Disorder 7-item (GAD-7) Scale</measure>
    <time_frame>Measured at 2-week study visit</time_frame>
    <description>GAD-7 is a scale that measures symptoms of anxiety in the prior 2 weeks on a 0-21 scale, with higher scores indicating worsening anxiety and a score of 10 or higher consistent with a diagnosis of generalized anxiety disorder. Investigators will assess the difference in mean GAD-7 score in the intervention versus control arms of the study at the 2-week study visit. Investigators will also determine the proportion with new GAD-7 score greater than or equal to 10 in each arm.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>4-week assessment of Preparedness for Shared Decision Making (PrepDM) Scale</measure>
    <time_frame>Measured at 4-week study visit</time_frame>
    <description>The PrepDM Scale will be measured for all participants with respect to the investigator-designed educational resource (research intervention) and mean score will be compared for participants in the intervention (4 weeks of exposure) versus control arms (2 weeks of exposure). PrepDM scores range on a scale from 0 to 100 with higher scores indicating a higher perceived level of preparation for decision making.</description>
  </other_outcome>
  <other_outcome>
    <measure>4-week assessment for confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey)</measure>
    <time_frame>Measured at 4-week study visit</time_frame>
    <description>Change in confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey) will be assessed from baseline to 4-weeks for participants in the intervention arm and from 2-week to 4-week study visits for participants in the Attention Control arm. Mean difference in the knowledge score (range -28 to +28) will be compared between study arms. Higher scores indicate more knowledge about lung transplant.</description>
  </other_outcome>
  <other_outcome>
    <measure>4-week assessment for Decisional Conflict Scale</measure>
    <time_frame>Measured at 4-week study visit</time_frame>
    <description>Change in Decisional Conflict Scale will be assessed from baseline to 4-weeks for participants in the intervention arm and from 2-week to 4-week study visits for participants in the Attention Control arm. Difference in the mean change in Decisional Conflict Scale will be compared between study arms. Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict].</description>
  </other_outcome>
  <other_outcome>
    <measure>4-week assessment for Likert-scale rating of preparedness to discuss lung transplant</measure>
    <time_frame>Measured at baseline, 2-week and 4-week study visits</time_frame>
    <description>Evaluate the proportion &quot;Very prepared&quot; at baseline, 2 weeks and 4 weeks in the intervention and control arms. Compare proportions across study arms at each time point.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time spent using the research website</measure>
    <time_frame>Baseline to 2-week study visit</time_frame>
    <description>Average time spent using the research website from baseline to 2 weeks will be compared across study arms. Further, time spent using the investigator-designed website will be assessed as a predictor of: 1. change in confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey) from baseline to 2-week study visit, 2. change in Likert preparedness from baseline to 2-week study visit, 3. change in Decisional Conflict Scale from baseline to 2-week study visit, and 4. mean PrepDM Scale at 2-weeks.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Access to an investigator-designed web-based educational resource with information about lung transplant for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Access to a publicly available web-based educational resource with information about transplant for two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Investigator-designed lung transplant education resource (Research Intervention)</intervention_name>
    <description>Participants will access the investigator-designed educational resource via their login to a secure website. After two weeks, participants will gain access to the publicly available website (attention control) and will have an additional two weeks of access to both of these resources.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Publicly available transplant education resource (Attention Control)</intervention_name>
    <description>Participants will access the publicly available education resource via their login to a secure website. After two weeks, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional two weeks of access to both of these resources.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cystic fibrosis&#xD;
&#xD;
          -  FEV1 less than or equal to 50% predicted (unless referred per MD recommendation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to provide informed consent&#xD;
&#xD;
          -  Patients who are lung transplant recipients&#xD;
&#xD;
          -  Unable to read or understand English to complete surveys or access the websites&#xD;
             (currently only available in English)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Ramos, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Bartlett, BS, CCRC</last_name>
    <phone>503-583-2869</phone>
    <email>lrejman@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Bartlett, BS, CCRC</last_name>
      <phone>503-583-2869</phone>
      <email>lrejman@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Ramos, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ramos KJ, Smith PJ, McKone EF, Pilewski JM, Lucy A, Hempstead SE, Tallarico E, Faro A, Rosenbluth DB, Gray AL, Dunitz JM; CF Lung Transplant Referral Guidelines Committee. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros. 2019 May;18(3):321-333. doi: 10.1016/j.jcf.2019.03.002. Epub 2019 Mar 27. Review.</citation>
    <PMID>30926322</PMID>
  </reference>
  <reference>
    <citation>Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, Campos SV, Christon LM, Cypel M, Dellgren G, Hartwig MG, Kapnadak SG, Kolaitis NA, Kotloff RM, Patterson CM, Shlobin OA, Smith PJ, Sol√© A, Solomon M, Weill D, Wijsenbeek MS, Willemse BWM, Arcasoy SM, Ramos KJ. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021 Nov;40(11):1349-1379. doi: 10.1016/j.healun.2021.07.005. Epub 2021 Jul 24.</citation>
    <PMID>34419372</PMID>
  </reference>
  <reference>
    <citation>Ramos KJ, Hobler MR, Engelberg RA, Curtis JR, Zander MI, Howard SS, Goss CH, Aitken ML. Addressing lung transplant with adults with cystic fibrosis: A qualitative analysis of patients' perspectives and experiences. J Cyst Fibros. 2019 May;18(3):416-419. doi: 10.1016/j.jcf.2019.04.007. Epub 2019 Apr 17.</citation>
    <PMID>31003953</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>December 8, 2021</last_update_submitted>
  <last_update_submitted_qc>December 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Kathleen Ramos</investigator_full_name>
    <investigator_title>Assistant Professor, School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Lung Transplantation</keyword>
  <keyword>Lung Disease</keyword>
  <keyword>Decision Support Tool</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) may be shared with other researchers for secondary analyses with the approval of the appropriate Human Subjects Division(s) and the study's principal investigator (PI).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will become available after publication of the results of the primary analyses of the study. The data will be available for up to 3 years after the end of the study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers with appropriate clinical research training and/or mentorship will be allowed to have access to IPD after approval is obtained from Human Subjects Division(s) and the study PI.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

